Phase 2 Trial of Ibudilast Shows Slowing of Brain Shrinkage in Progressive MS
Patients living with primary progressive multiple sclerosis have eagerly been awaiting the results from phase 2 of the ibudilast study. It is the hope...
Health Canada approval last week of multiple sclerosis drug ‘absolutely a game-changer’
Global News - Joseph Petrilli said he cried for a long time when he heard that Health Canada approved a new drug that could...
Annual MS Awareness Video – We want your Videos!
It’s time for MS & Me’s annual MS Awareness video. We have once again partnered with MyCounterpane to bring you this video composed of...
Multiple sclerosis ”game changer” drug gets government subsidy in Australia
Melanie Row was enjoying a family holiday on the Gold Coast in 2016 when she noticed she didn't have control of her right thumb.The...
Introducing the Barts MS Charity – “Lets Find Answers Together”
What is the objective of Barts MS Charity?To enable Barts-MS to undertake hard-to-fund, or to prime important, MS research projects.Our first key objective is to...
New Inroads Against Multiple Sclerosis
JAMA recently published their interviews with two MS Specaists focusing on the medical progress against multiple sclerosis (MS) in 2017 with the approval by the...
Roche seeks partners for remyelination therapies
Roche Holding AG is seeking a partner with experimental drugs that might help repair the damage caused to the nervous system by multiple sclerosis...
CMSC 2017 May 24th -27th
International Neurologists and MS Researchers will Present Opening Lectures, May 24-27Hackensack, NJ, May 8, 2017 (Newswire.com) - The preeminent conference for multiple sclerosis health...
My MS and Me Story
MS and Me blogger Debra Gaston Brigman shares her most recent blog written last month. It is a very personal account of her MS...
Biogen’s 8% Increase to Some MS Medications Could Provide a Boost in 2018
Market Watch reports Biogen Inc.'s BIIB, +4.90% recent price increases on multiple sclerosis drugs "could provide lift into '18," according to RBC Capital Markets...
